PDCD1 and neoplasm: In the phase I/II START-001 trial (NCT05592626), invikafusp alfa showed the most significant efficacy with two confirmed partial responses (ORR = 50%) among heavily pretreated patients, including anti-PD-1/PD-L1 therapy, with high tumor mutational burden (TMB-H) MSS CRC [129].